MedWatch

Chemometec rolls out future sales hope - starting with American biotech incubators

Chemometec and CEO Michael Eising have launched and sold the first unit of cell counter NC-202, which is an upgrade of the company's best-selling product. The firm is starting sales at brand new biotech companies.

Michael Eising, CEO of Chemometec. Photo: PR / Chemometec

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles